Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Persephoni BioPartners is a biotechnology venture studio founded by Hilary Schultz, dedicated to partnering with innovators at the earliest stages of development. Established in the United States, the firm focuses on transforming scientific breakthroughs into real-world therapeutics. The organization collaborates with academic institutions, investors, and industry leaders to build high-impact biotech companies.
Currently, Persephoni BioPartners manages a portfolio of four companies and operates in the pre-seed, seed, and seed-plus investment stages. The firm emphasizes foundational science and strong preclinical data in its investment strategy, aiming to create scalable business models that contribute to long-term growth. Their commitment to the biotech sector is reflected in their active engagement with emerging companies that have the potential to significantly impact human health.
Persephoni BioPartners invests primarily in early-stage biotech companies that demonstrate foundational, differentiated science with strong preclinical data. Their investment strategy is centered on therapeutic, diagnostic, or platform-based innovations that can positively affect human health. The firm prioritizes ventures in specific areas, including autoimmunity, oncology, and viral diseases, particularly those associated with Epstein-Barr Virus (EBV).
Investment checks typically occur at the pre-seed, seed, and seed-plus stages, allowing Persephoni BioPartners to support companies from their inception. They seek startups with robust intellectual property and a clear path to clinical relevance, emphasizing scalable business models designed for sustainable growth. This focus on early-stage investments positions them as a key player in the biotech sector, fostering collaborations that enhance the potential for impactful innovations.
Persephoni BioPartners has a notable portfolio consisting of four companies:
These companies exemplify Persephoni BioPartners' commitment to investing in high-impact biotech innovations that address significant health challenges.
Hilary Schultz - CEO & Founder: Hilary has extensive experience in the biotech sector and leads the strategic direction of Persephoni BioPartners.
William Heath - Chief Scientific Officer: William brings a wealth of scientific expertise, focusing on the evaluation of potential investments.
Bruce Ricart - Chief Operating Officer: Bruce oversees the operational aspects of the firm, ensuring efficient management of portfolio companies.
Christopher Potts - Chief Business Officer: Christopher is responsible for business development and partnerships, leveraging his background in the biotech industry.
Maryam Mokhtarzadeh - Chief Medical Officer: Maryam provides medical insights and guidance on clinical strategies for portfolio companies.
Tarul Kode - Vice President of Partnerships & Alliance Management: Tarul manages collaborations with academic and industry partners.
Michaela Copp - Director, Program Lead: Michaela leads specific programs within the firm, focusing on portfolio development.
Sarra Djemil - Director, Program Lead: Sarra also oversees program initiatives, contributing to the firm's strategic goals.
Andrew Petryna - Director, Lab Operations & Program Lead: Andrew manages lab operations and supports program development.
Lisa Puccetti - Director, Business Operations: Lisa handles business operations, ensuring smooth functioning of the firm.
Anna Cotten - Venture Partner: Anna provides strategic insights and guidance as a venture partner.
William A. Hawkins - Advisor: William offers advisory support based on his extensive experience in the biotech field.
Emma Moulton - Senior Associate: Emma supports investment analysis and portfolio management.
Andrea Balukova - Venture Fellow: Andrea contributes to research and analysis within the firm.
Marissa Coppin - Research Fellow: Marissa assists in research initiatives related to portfolio companies.
Diana Drago-Garcia - Fellow: Diana supports various projects within the firm.
Raven Moten - Fellow: Raven contributes to research and development efforts.
Benjamin Kannel - Fellow: Benjamin assists with research initiatives and portfolio support.
Startups interested in pitching to Persephoni BioPartners should submit their proposals through the firm's website. The pitch deck should include details about the scientific innovation, market potential, and business model. While specific response time expectations are not disclosed, founders are encouraged to provide a comprehensive overview of their project to facilitate evaluation.
Persephoni BioPartners runs a program under the same name, focusing on supporting early-stage biotech companies. This program aims to provide resources, mentorship, and access to a network of industry leaders and academic institutions. Startups interested in participating can apply through the firm's website, where they can find more information about eligibility and application procedures.
As of October 2023, Persephoni BioPartners has been actively building its portfolio, which currently includes four notable companies. The firm continues to focus on collaborations with academic institutions and industry leaders to foster high-impact biotech innovations.
Recent activities include the ongoing development of their portfolio companies, particularly in the areas of autoimmunity and oncology. The firm remains committed to supporting early-stage biotech ventures that align with their investment thesis.
What are Persephoni BioPartners' investment criteria?
Persephoni BioPartners invests in early-stage biotech companies that demonstrate foundational science and strong preclinical data. They prioritize ventures with robust intellectual property and scalable business models aimed at long-term growth.
How can startups apply or pitch to Persephoni BioPartners?
Startups interested in partnering with Persephoni BioPartners can apply through their website. They encourage innovators to submit their proposals detailing their scientific breakthroughs and business models.
What makes Persephoni BioPartners different from other venture firms?
Persephoni BioPartners operates as a venture studio, actively collaborating with academic institutions and industry leaders to build high-impact biotech companies. This hands-on approach differentiates them from traditional venture capital firms.
What is the geographic scope of Persephoni BioPartners' investments?
The firm focuses on investments within the United States, targeting early-stage biotech companies that have the potential to impact human health.
What is the typical check size for investments?
Persephoni BioPartners invests at the pre-seed, seed, and seed-plus stages, although specific check sizes are not publicly disclosed. They focus on providing the necessary capital to support early-stage development.
What kind of post-investment involvement does Persephoni BioPartners have?
Persephoni BioPartners engages closely with their portfolio companies, providing operational support, mentorship, and access to their extensive network of academic and industry leaders to enhance growth opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.